Methotrexate and its therapeutic antagonists caffeine and theophylline, target a motogenic T‐cell mechanism driven by thrombospondin‐1 (TSP‐1)

@article{Talme2016MethotrexateAI,
  title={Methotrexate and its therapeutic antagonists caffeine and theophylline, target a motogenic T‐cell mechanism driven by thrombospondin‐1 (TSP‐1)},
  author={T. Talme and E. Bergdahl and K. Sundqvist},
  journal={European Journal of Immunology},
  year={2016},
  volume={46}
}
Methotrexate (MTX) is a widely used treatment for inflammatory diseases such as rheumatoid arthritis and psoriasis, based on the concept that it is immunosuppressive. Its mechanism of action, however, remains unclear, although it is thought to depend on adenosine. Caffeine and theophylline, which have several targets including adenosine receptors, have been shown to suppress the beneficial clinical effects of MTX. Here we show that MTX and caffeine and theophylline differentially affect a… Expand
Thrombospondin-1/CD47 Interaction Regulates Th17 and Treg Differentiation in Psoriasis
Decoding inflammation, its causes, genomic responses, and emerging countermeasures
T Cell Motility─How Is It Regulated?

References

SHOWING 1-10 OF 106 REFERENCES
Methotrexate—how does it really work?
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
...
1
2
3
4
5
...